JP2023534922A - ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 - Google Patents

ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 Download PDF

Info

Publication number
JP2023534922A
JP2023534922A JP2023500328A JP2023500328A JP2023534922A JP 2023534922 A JP2023534922 A JP 2023534922A JP 2023500328 A JP2023500328 A JP 2023500328A JP 2023500328 A JP2023500328 A JP 2023500328A JP 2023534922 A JP2023534922 A JP 2023534922A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
antibody
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534922A5 (https=
Inventor
ゲボルグ グリゴリアン，
ジョン イングラハム，
チュク ルン レオン，
ロス スティーブン フェダーマン，
ロビン ジェフリー グリーン，
ヴィンセント シュエ，
クレイグ オーウェン マッケンジー，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー filed Critical フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Publication of JP2023534922A publication Critical patent/JP2023534922A/ja
Publication of JP2023534922A5 publication Critical patent/JP2023534922A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023500328A 2020-07-06 2021-07-06 ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 Pending JP2023534922A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063048588P 2020-07-06 2020-07-06
US63/048,588 2020-07-06
US202063070038P 2020-08-25 2020-08-25
US63/070,038 2020-08-25
PCT/US2021/040533 WO2022010912A1 (en) 2020-07-06 2021-07-06 Antigen binding molecules targeting sars-cov-2

Publications (2)

Publication Number Publication Date
JP2023534922A true JP2023534922A (ja) 2023-08-15
JP2023534922A5 JP2023534922A5 (https=) 2024-07-17

Family

ID=77155889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500328A Pending JP2023534922A (ja) 2020-07-06 2021-07-06 ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子

Country Status (8)

Country Link
US (1) US12473560B2 (https=)
EP (1) EP4175984A1 (https=)
JP (1) JP2023534922A (https=)
KR (1) KR20230035346A (https=)
AU (1) AU2021305067A1 (https=)
CA (1) CA3183373A1 (https=)
IL (1) IL299631A (https=)
WO (1) WO2022010912A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010912A1 (en) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054469A1 (en) * 2003-12-05 2005-06-16 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
UA119328C2 (uk) 2013-08-09 2019-06-10 Астеллас Фарма Інк. Антитіло до тslp-рецептора людини
CN108064243B (zh) 2014-10-01 2021-08-27 免疫医疗有限公司 对lox1具有特异性的结合蛋白及其用途
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
WO2020180398A1 (en) 2019-01-14 2020-09-10 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
EP4121454A1 (en) 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
US11028167B1 (en) * 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
US20240059757A1 (en) 2020-04-14 2024-02-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
US20230174628A1 (en) 2020-04-28 2023-06-08 Peking University Anti-novel coronavirus monoclonal antibody and application thereof
WO2021226560A1 (en) 2020-05-08 2021-11-11 Vir Biotechnology, Inc. Antibodies against sars-cov-2
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
WO2022010912A1 (en) 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
WO2022026475A2 (en) 2020-07-27 2022-02-03 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
KR20230127305A (ko) 2020-12-29 2023-08-31 발-첨, 리미티드 파트너십 Covid-19에 대한 중화 단일클론 항체
WO2022159685A2 (en) 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
KR20240035758A (ko) 2021-05-24 2024-03-18 비르 바이오테크놀로지, 인코포레이티드 조작된 폴리펩타이드
WO2022271863A1 (en) 2021-06-23 2022-12-29 Chan Zuckerberg Biohub, Inc. Coronavirus neutralizing compositions and associated methods
WO2023028603A2 (en) 2021-08-27 2023-03-02 Humabs Biomed Sa Engineered compositions
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
EP4519310A1 (en) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054469A1 (en) * 2003-12-05 2005-06-16 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUBBINS, MICHAEL J. ET AL., MOLECULAR IMMUNOLOGY, vol. 42, no. 1, JPN6025027339, 2005, pages 125 - 136, ISSN: 0005633727 *

Also Published As

Publication number Publication date
US20230279081A1 (en) 2023-09-07
IL299631A (en) 2023-03-01
US12473560B2 (en) 2025-11-18
CA3183373A1 (en) 2022-01-13
KR20230035346A (ko) 2023-03-13
AU2021305067A1 (en) 2023-02-09
EP4175984A1 (en) 2023-05-10
WO2022010912A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
US11987616B2 (en) Antigen binding molecules targeting SARS-CoV-2
US11981725B2 (en) Antigen binding molecules targeting SARS-CoV-2
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
US11993644B2 (en) Antigen binding molecules targeting SARS-CoV-2
JP2023518849A (ja) 重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
JP2024502046A (ja) Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体
CN110088131B (zh) 抗chikv抗体及其用途
WO2021245184A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
TW202227507A (zh) 用於預防或治療病毒及其他微生物感染之組合物
CN115515976A (zh) 冠状病毒抗体
JP2025537301A (ja) Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
CA3090327A1 (en) Binding molecule having neutralizing activity against middle east respiratory syndrome-coronavirus
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
US11359007B2 (en) Anti-SARS-CoV-2 neutralizing antibodies
CN116547005A (zh) 靶向SARS-CoV-2的抗原结合分子
CA3102329C (en) Novel anti-cd39 antibodies
CN116635410A (zh) 靶向SARS-CoV-2的抗原结合分子
WO2025230768A1 (en) Compositions and methods related to coronavirus therapies
CN117062624A (zh) 抗covid-19中和单克隆抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251219